- Home
- DINO vs ROIV Comparison
DINO vs ROIV Comparison
Compare DINO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DINO
- ROIV
- Stock Information
- Founded
- DINO 1947
- ROIV 2014
- Country
- DINO United States
- ROIV United Kingdom
- Employees
- DINO N/A
- ROIV N/A
- Industry
- DINO Oil & Gas Production
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DINO Energy
- ROIV Health Care
- Exchange
- DINO Nasdaq
- ROIV Nasdaq
- Market Cap
- DINO 9.0B
- ROIV 8.4B
- IPO Year
- DINO N/A
- ROIV N/A
- Fundamental
- Price
- DINO $45.00
- ROIV $12.06
- Analyst Decision
- DINO Buy
- ROIV Strong Buy
- Analyst Count
- DINO 10
- ROIV 10
- Target Price
- DINO $61.33
- ROIV $17.39
- AVG Volume (30 Days)
- DINO 2.2M
- ROIV 5.0M
- Earning Date
- DINO 10-31-2024
- ROIV 11-11-2024
- Dividend Yield
- DINO 4.43%
- ROIV N/A
- EPS Growth
- DINO N/A
- ROIV N/A
- EPS
- DINO 6.22
- ROIV 5.65
- Revenue
- DINO $31,438,583,000.00
- ROIV $158,303,000.00
- Revenue This Year
- DINO N/A
- ROIV $45.51
- Revenue Next Year
- DINO N/A
- ROIV $37.40
- P/E Ratio
- DINO $7.27
- ROIV $2.11
- Revenue Growth
- DINO N/A
- ROIV 101.44
- 52 Week Low
- DINO $44.07
- ROIV $8.25
- 52 Week High
- DINO $64.16
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- DINO 40.95
- ROIV 59.17
- Support Level
- DINO $44.07
- ROIV $12.11
- Resistance Level
- DINO $46.40
- ROIV $13.06
- Average True Range (ATR)
- DINO 1.32
- ROIV 0.39
- MACD
- DINO -0.22
- ROIV -0.00
- Stochastic Oscillator
- DINO 17.24
- ROIV 47.59
About DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.